key: cord-261929-x688qqdr
authors: Geskin, Larisa J.; Trager, Megan H.; Aasi, Sumaira Z.; Bickers, David R.; Carvajal, Richard D.; Nghiem, Paul; Taback, Bret; Zeitouni, Nathalie C.; Samie, Faramarz H.
title: Perspectives on the Recommendations for Skin Cancer Management During the COVID-19 Pandemic
date: 2020-05-06
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.05.002
sha: 
doc_id: 261929
cord_uid: x688qqdr

nan

Therapy-related travel for the high-risk category (high-risk cSCC, invasive, thick and 56 ulcerated melanoma, MCC, tumors with aggressive histology or in sensitive areas) must be 57 weighed against each patient's risks. For rapidly growing cSCC, particularly of the head and 58 neck (eyes, ears, lips, mouth) and symptomatic lesions, more immediate treatment may be 59 considered. MMS may be utilized for high-risk SCC and rare cancers (including undifferentiated 60 pleiomorphic sarcoma and adnexal tumors with concern for rapidly developing metastasis). To Telemedicine visits should be prioritized, limiting in-person visits for biopsies of highly 71 suspicious lesions and for in-office therapies for the highest-risk cancers. This pandemic presents 72 evolving challenges, and we must continue to provide optimal treatment for our patients while 73 preventing global spread of the disease and preserving resources. 

Managing Cancer Care During the COVID-79 19 Pandemic: Agility and Collaboration Toward a Common Goal

A new evidence-based risk 82 stratification system for cutaneous squamous cell carcinoma into low, intermediate, and high risk 83 groups with implications for management